Hematology Quality Metrics
This page was last updated on February 23, 2017.
These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.
Intended Audience and Patient Population:
Any hematologist caring for patients age 18 years and older with myelodysplastic syndrome, acute leukemias, multiple myeloma, or chronic lymphocytic leukemia.
back to top
- Overview of Measure Development Process
- Myelodysplastic Syndrome and Acute Leukemias
CMS Measure #67 (Hematology Measure #1) - Baseline cytogenetic testing performed on bone marrow
- Myelodysplastic Syndrome
CMS Measure #68 (Hematology Measure #2) - Documentation of baseline iron stores in patients receiving erythropoietin therapy
- Multiple Myeloma
CMS Measure #69 (Hematology Measure #3) - Treatment with bisphosphonates
- Chronic Lymphocytic Leukemia
CMS Measure #70 (Hematology Measure #4) - Baseline flow cytometry